Genomic Diagnostics Across Every Specialty
Life Readers coordinates molecular testing from our network of accredited partner laboratories. Browse our test catalogue below and contact us to discuss ordering.
Cancer
Oncology Genomics
Precision oncology depends on knowing the molecular driver of each tumour. Our network provides comprehensive somatic profiling panels used to guide targeted therapy selection, immunotherapy eligibility, and clinical trial enrolment.
Comprehensive Solid Tumour Panel
Multi-gene NGS panel covering 500+ cancer-associated genes. Identifies actionable SNVs, indels, CNVs, and gene fusions.
Haematological Malignancy Panel
Targeted panel for leukaemia, lymphoma, and myeloma — covering somatic mutations, chromosomal rearrangements, and MRD monitoring.
MSI / TMB Assessment
Microsatellite instability and tumour mutational burden quantification — key biomarkers for immunotherapy eligibility.
BRCA1/2 Somatic Testing
Tumour-based BRCA1 and BRCA2 analysis for PARP inhibitor eligibility in ovarian, breast, and prostate cancers.
Drug Response
Pharmacogenomics
Pharmacogenomic testing identifies genetic variants that affect how patients metabolize and respond to medications — enabling safer prescribing, preventing adverse events, and optimizing dosing.
Core PGx Panel
Tests 12 key metabolizing enzymes (CYP2D6, CYP2C19, CYP2C9, TPMT, DPYD, and more) relevant to psychiatry, cardiology, oncology, and anaesthesiology.
Oncology PGx Panel
Focused on chemotherapy-related variants: DPYD (5-FU toxicity), UGT1A1 (irinotecan), and TPMT (thiopurines).
Cardiovascular PGx
Warfarin dosing (VKORC1, CYP2C9), clopidogrel response (CYP2C19), and statin myopathy risk (SLCO1B1).
Germline
Inherited Disease Testing
Germline genomic testing identifies inherited variants that predispose patients and their families to disease. Our panels are validated against African population variant databases where available.
Hereditary Cancer Panel
Germline analysis of 30+ genes associated with hereditary breast, ovarian, colorectal, and other cancer syndromes. Includes BRCA1/2, MLH1, MSH2, APC, and more.
Cardiogenetics Panel
Variants underlying hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmias (long QT, Brugada), and channelopathies.
Carrier Screening
Population-level screening for autosomal recessive conditions: sickle cell disease, G6PD deficiency, thalassaemia, and cystic fibrosis.
Rare Disease
Rare Disease Diagnostics
Rare disease diagnosis often requires the deepest genomic interrogation. Our network provides specialist sequencing capabilities for patients with undiagnosed and rare conditions.
Whole Exome Sequencing (WES)
Sequencing of all ~22,000 protein-coding genes. The gold standard for diagnosing patients with suspected rare Mendelian disease.
Whole Genome Sequencing (WGS)
Comprehensive sequencing of the entire genome — including non-coding regions implicated in regulatory variants and structural rearrangements.
Chromosomal Microarray
Detection of copy number variants (CNVs) and regions of homozygosity — key in paediatric intellectual disability, developmental delay, and dysmorphic features.
Non-Invasive
Liquid Biopsy
Liquid biopsy analyses circulating tumour DNA (ctDNA) in blood — enabling cancer detection, treatment monitoring, and minimal residual disease assessment without invasive tissue sampling.
Plasma ctDNA Panel
Multi-cancer early detection and treatment response monitoring using cell-free DNA sequencing from a standard blood draw.
MRD Monitoring
Ultrasensitive detection of residual disease after treatment completion for haematological malignancies and solid tumours.
Infection
Infectious Disease Genomics
Pathogen genomics is critical for AMR surveillance, outbreak investigation, and precision infection management — especially in Africa's high-burden infectious disease landscape.
TB Whole Genome Sequencing
Comprehensive drug resistance profiling of M. tuberculosis — far superior to conventional DST, covering all first- and second-line drugs.
HIV Drug Resistance Genotyping
Sequencing of HIV reverse transcriptase, protease, and integrase genes to guide antiretroviral therapy.
Metagenomics / Unknown Pathogen
Unbiased sequencing to identify and characterise unknown or unexpected pathogens in complex clinical samples.
Need a test not listed here?
Our network can source specialist genomic testing beyond our standard catalogue. Contact us to discuss your clinical needs.